Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Laekna, Inc. ( (HK:2105) ) has issued an announcement.
Laekna, Inc. has submitted an Investigational New Drug application to the U.S. FDA for LAE103, a monoclonal antibody aimed at treating sarcopenic obesity and muscle-related diseases. This move signifies the company’s commitment to developing precision therapies for metabolic patients, potentially enhancing its position in the biotechnology sector.
The most recent analyst rating on (HK:2105) stock is a Buy with a HK$26.46 price target. To see the full list of analyst forecasts on Laekna, Inc. stock, see the HK:2105 Stock Forecast page.
More about Laekna, Inc.
Laekna, Inc. operates in the biotechnology industry, primarily focusing on the development of innovative therapies for metabolic diseases. The company is engaged in advancing monoclonal antibodies, such as LAE103, targeting conditions like sarcopenic obesity and muscle-related diseases.
Average Trading Volume: 4,708,100
Technical Sentiment Signal: Strong Buy
See more data about 2105 stock on TipRanks’ Stock Analysis page.